Splanchnic venous thrombosis may suggest undiagnosed cancer
the ONA take:
According to a new study published in the journal Blood, researchers have found that a blood clot in an abdominal vein may suggest undiagnosed cancer, and these clots may indicate reduced survival in patients with liver and pancreatic cancer.
For the study, researchers analyzed the risk for subsequent cancer diagnosis of 1,191 Danish patients who were diagnosed with abdominal clots and evaluated the survival of those with a splanchnic venous thrombosis (SVT) and cancer versus those without cancer.
Results showed that compared with the general Danish population, patients who developed an SVT were 33 times more likely to be diagnosed with cancer during the first 3 months after SVT diagnosis. In addition, patients with an SVT and liver or pancreatic cancer had a significantly worse 3-month survival compared with those without an SVT.
Researchers also found that patients diagnosed with an SVT were more likely to develop a myeloproliferative neoplasm beyond 12 months after SVT diagnosis.
A blood clot in an abdominal vein may suggest undiagnosed cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|